Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA)’s share price hit a new 52-week low during trading on Friday . The company traded as low as $8.94 and last traded at $8.94, with a volume of 1580 shares changing hands. The stock had previously closed at $9.86.

A number of brokerages have commented on KNSA. ValuEngine raised Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. JMP Securities cut their target price on Kiniksa Pharmaceuticals to $35.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 14th. They noted that the move was a valuation call. Zacks Investment Research raised Kiniksa Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research report on Friday, August 16th. Finally, Wedbush reaffirmed a “buy” rating on shares of Kiniksa Pharmaceuticals in a research report on Wednesday, August 14th. Five equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average price target of $26.50.

The business has a 50-day simple moving average of $12.31 and a 200 day simple moving average of $15.22. The firm has a market cap of $574.36 million, a P/E ratio of -2.54 and a beta of -1.56.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Monday, August 12th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.03. As a group, equities research analysts anticipate that Kiniksa Pharmaceuticals Ltd will post -3.47 earnings per share for the current fiscal year.

A number of hedge funds have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its position in Kiniksa Pharmaceuticals by 33.1% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,832 shares of the company’s stock valued at $52,000 after buying an additional 952 shares in the last quarter. BNP Paribas Arbitrage SA increased its position in Kiniksa Pharmaceuticals by 1,131.7% during the 1st quarter. BNP Paribas Arbitrage SA now owns 2,685 shares of the company’s stock valued at $48,000 after buying an additional 2,467 shares in the last quarter. Bank of New York Mellon Corp increased its position in Kiniksa Pharmaceuticals by 20.5% during the 4th quarter. Bank of New York Mellon Corp now owns 20,570 shares of the company’s stock valued at $578,000 after buying an additional 3,499 shares in the last quarter. Parametric Portfolio Associates LLC increased its position in Kiniksa Pharmaceuticals by 17.9% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 31,595 shares of the company’s stock valued at $428,000 after buying an additional 4,787 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Kiniksa Pharmaceuticals by 61.2% during the 1st quarter. Rhumbline Advisers now owns 12,811 shares of the company’s stock valued at $231,000 after buying an additional 4,862 shares in the last quarter. 30.15% of the stock is owned by institutional investors.

About Kiniksa Pharmaceuticals (NASDAQ:KNSA)

Kiniksa Pharmaceuticals, Ltd., a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need worldwide. Its clinical-stage product candidates include Rilonacept, which is in Phase II clinical trials for the treatment of recurrent pericarditis, an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody for the treatment of giant cell arteritis; and KPL-716, a monoclonal antibody, which is in Phase 1a/1b clinical trial for the treatment of prurigo nodularis and atopic dermatitis.

Recommended Story: Operating Income

Receive News & Ratings for Kiniksa Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kiniksa Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.